The George Group - Pharmacogenomic Technologies
Research group led by Dr Amee George.
Research themes
About
Associate Professor Amee George leads a specific research program into disorders of ribosome biogenesis (ribosomopathies) and the molecular mechanism(s) and signalling pathways which link this process to the nucleolus, a key structure in ribosome biogenesis. She is also a national specialist in high-throughput and high-content screening, leading the ANU Centre for Therapeutic Discovery.
Closely collaborating with the Hannan Group, the George Group has a research interest in:
- identifying disease biomarkers (genotype-phenotype) and therapeutic targets for drug discovery,
- utilising functional (RNAi/CRISPR) and molecule/biologic approaches and high-content imaging readouts
- developing new approaches to model disease in vitro, with a view to use these models for drug discovery projects (including complex 2D and 3D cellular models).
Publications
Projects
Members
Leader
Associate Professor in Pharmacogenomic Technologies
Lead, ANU Centre for Therapeutic Discovery (ACTD)
Group Leader
Researcher
Research Technician
Postdoctoral fellow
Research Fellow
Research support officer
Research Support Officer
Technologies Specialist - ANU Centre for Therapeutic Discovery
Senior Technologies Officer
Technologies Officer
News
Defects in the cellular protein factories can cause rare disorders known as ribosomopathies. A team led by Dr Amee George looks to find therapeutic targets through unravelling the molecular mechanisms underlying the diseases.
Zara and Mila, aged 8 and 9, have raised $12,760 to support brain cancer research at JCSMR.